PCOS Lab Panel: The Complete Guide to Testing for Polycystic Ovary Syndrome

Quick answer: The standard PCOS lab panel includes androgens (total testosterone, free testosterone, DHEA-S), reproductive hormones (LH, FSH, estradiol, AMH, prolactin), a full metabolic panel (fasting insulin, fasting glucose, HOMA-IR, HbA1c, lipids), and thyroid function (TSH, free T3, free T4). No single test diagnoses PCOS — the diagnosis requires integrating lab findings with clinical symptoms and, where appropriate, pelvic ultrasound.

What Is PCOS and Why Does Lab Testing Matter? 

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, estimated to affect between 8–13% of the global female population — yet up to 70% of those affected remain undiagnosed [1]. The delay in diagnosis is not usually attributable to lack of symptoms; most women who eventually receive a PCOS diagnosis have been symptomatic for years. The problem, in large part, is that PCOS lacks a single definitive test, and the symptom picture — irregular periods, acne, hair thinning, weight changes, difficulty conceiving — overlaps considerably with other conditions, from thyroid disease to hyperprolactinaemia to non-classical congenital adrenal hyperplasia (CAH).

This is exactly where laboratory testing becomes indispensable. Labs do two critical things simultaneously: they help establish the hormonal pattern consistent with PCOS, and they rule out the conditions that can convincingly impersonate it. Neither job is trivial.

The Rotterdam Criteria — what most clinicians use

PCOS diagnosis in clinical practice is governed by the 2003 Rotterdam consensus criteria, which require at least two of the following three features [2]:

1. Oligo- or anovulation — irregular, infrequent, or absent menstrual cycles
2. Clinical or biochemical signs of hyperandrogenism — excess androgens on blood tests, or their physical manifestations (hirsutism, acne, alopecia)
3. Polycystic ovarian morphology (PCOM) on ultrasound — 12 or more follicles per ovary, or increased ovarian volume

The important implication of this criteria is that you can receive a PCOS diagnosis without cysts on ultrasound, and without irregular periods, provided the other features are present. A woman with regular cycles but elevated androgens and polycystic ovaries still meets criteria. This is why labs — particularly androgen measurement — are not optional; they may be the deciding feature in an otherwise ambiguous presentation.

The four PCOS phenotypes and why they matter for testing

Because the Rotterdam Criteria allow for three possible two-of-three combinations (plus one three-of-three), PCOS presents in four distinct phenotypes [3]:

Phenotype matters for which labs take priority. A woman with phenotype C may have entirely normal testosterone on a standard test yet show subtle free androgen elevation or SHBG suppression. A woman with phenotype D may have minimal metabolic abnormality but significant ovulatory disruption. One lab panel does not serve all presentations equally well — which is precisely why this guide goes beyond the standard checklist.

The Core PCOS Hormone Panel 

1. Total testosterone — the anchor of PCOS hormone testing

Total testosterone is the first androgen test most clinicians order, and with good reason — it is elevated in approximately 60–80% of women with PCOS depending on the phenotype [4]. However, total testosterone has a meaningful limitation in the PCOS context: because a significant fraction of circulating testosterone is bound to sex hormone-binding globulin (SHBG) and therefore biologically inactive, total testosterone can appear normal even when the free, active fraction is elevated.

Reference ranges in adult women (typically):

• Total testosterone: 15–70 ng/dL (0.5–2.4 nmol/L)
• Mildly elevated in PCOS: 70–150 ng/dL
• Total testosterone >150–200 ng/dL should prompt investigation for androgen-secreting tumour

Timing matters acutely for this test: testosterone peaks in the morning and is best drawn between 7–10am in the early follicular phase (days 2–5 of the cycle).

2. Free testosterone and SHBG — the more precise markers

Free testosterone — the fraction not bound to SHBG or albumin — is the biologically active form, and it is arguably more clinically informative than total testosterone in PCOS. Studies have consistently shown that free testosterone measurement identifies hyperandrogenism in women where total testosterone tests within normal limits [5].

SHBG (sex hormone-binding globulin) deserves its own discussion. In PCOS, insulin resistance suppresses hepatic SHBG production, lowering circulating SHBG and thereby increasing free androgen availability — even when total testosterone looks unremarkable. A low SHBG level (typically <30–40 nmol/L in reproductive-age women) is itself a red flag and should prompt calculation of the Free Androgen Index (FAI):

FAI = (Total Testosterone ÷ SHBG) × 100

A FAI above 4–5 is generally considered elevated in women, and in clinical research correlates strongly with both the clinical features and metabolic complications of PCOS [6].

3. DHEA-S — the adrenal androgen

Dehydroepiandrosterone sulphate (DHEA-S) originates almost exclusively from the adrenal glands rather than the ovaries. It is elevated in approximately 20–30% of women with PCOS [7], and when DHEA-S is disproportionately elevated relative to ovarian androgens, it suggests a predominantly adrenal androgen excess pattern — sometimes called "adrenal PCOS."

Clinically, this distinction matters because adrenal androgen excess may respond differently to lifestyle and pharmacological interventions, and because very high DHEA-S (>700 µg/dL) warrants investigation for adrenal pathology.

4. Androstenedione — often overlooked, sometimes critical

Androstenedione is a precursor to both testosterone and oestrogens, produced by both the ovaries and adrenal glands. It is elevated in a substantial proportion of women with PCOS and may be the only abnormal androgen in cases where testosterone is borderline normal [8]. Despite this, it is often absent from standard panels. In a comprehensive PCOS workup, particularly when clinical hyperandrogenism is present but testosterone is normal, androstenedione should be included.

5. LH and FSH — the brain–ovary communication signals

Luteinising hormone (LH) and follicle-stimulating hormone (FSH) are gonadotrophins secreted by the pituitary gland. In PCOS, the pulsatile pattern of GnRH release is disrupted, resulting in preferential LH secretion — hence the elevated LH:FSH ratio often cited in PCOS literature.

The LH:FSH ratio in clinical context:

A ratio of 2:1 or 3:1 (LH twice to three times higher than FSH) is frequently described as characteristic of PCOS. However, it is important to note that this finding is neither universal (present in roughly 40–60% of cases) nor specific [9]. A normal LH:FSH ratio absolutely does not exclude PCOS. These values are drawn in the early follicular phase and can be highly variable. Their primary utility is as corroborating evidence in an already-suggestive picture, not as a diagnostic threshold.

6. Estradiol — where it fits

Estradiol (E2) is often within normal range in PCOS but is usefully drawn at the same time as LH and FSH to interpret the full reproductive axis picture. Persistently elevated baseline oestradiol may suggest follicular cyst activity; very low oestradiol in a woman with oligomenorrhoea may point toward hypothalamic amenorrhoea as the primary diagnosis rather than PCOS.

Progesterone — testing for ovulation

A mid-luteal serum progesterone drawn approximately 7 days after confirmed or expected ovulation (typically around day 19–21 in a 28-day cycle) provides direct biochemical evidence of whether ovulation occurred. Values above 10 nmol/L (≈3 ng/mL) generally indicate ovulation; values below this in a woman with irregular cycles support anovulation as a feature.

This is a clinically underused test. Many women with PCOS receive the diagnosis of "irregular periods" without a progesterone test to confirm whether they are actually failing to ovulate — which has significant implications for fertility planning and treatment.

Prolactin — ruling out the mimicker

Hyperprolactinaemia can cause irregular cycles and anovulation in the absence of PCOS, and the two conditions share enough symptomatic overlap that prolactin measurement is a mandatory exclusion test in any PCOS workup. Mildly elevated prolactin (up to twice the upper limit of normal) can be seen in PCOS itself, likely due to increased oestrogen exposure. Values above 100–150 ng/mL should prompt MRI pituitary imaging to exclude prolactinoma [10].

AMH — PCOS's most consistent biomarker?

Anti-Müllerian hormone (AMH) is produced by the small antral follicles of the ovary, and in PCOS — where follicle development is arrested — AMH levels are characteristically two to three times higher than in women without PCOS [11]. This makes AMH one of the most consistent laboratory findings in the condition, present across all four phenotypes.

AMH is not currently part of the diagnostic criteria, but it is increasingly used in clinical practice to support the diagnosis, particularly in cases where ultrasound quality is limited (as is common in adolescents or women with high BMI). The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS acknowledges AMH as a reliable marker of polycystic ovarian morphology [12].

A practical caveat: AMH values vary significantly between assay platforms, and laboratories do not yet use a standardised reference range. An AMH above approximately 35–40 pmol/L (5–6 ng/mL) in a reproductive-age woman is broadly consistent with PCOS morphology, but this should always be interpreted alongside clinical context.

The PCOS Metabolic Panel — Insulin Resistance and Glucose 

This is arguably the most consequential section of a PCOS workup — and the one most frequently incomplete in standard clinical practice. Approximately 65–70% of women with PCOS have insulin resistance, irrespective of body weight [13]. Lean women with PCOS have insulin resistance at rates of 20–40%. Yet insulin and HOMA-IR are absent from most standard PCOS lab orders.

The metabolic consequences of untreated insulin resistance in PCOS are serious: a 4–7 times increased risk of type 2 diabetes, significantly elevated cardiovascular risk, and disproportionate rates of non-alcoholic fatty liver disease (NAFLD) [14]. Identifying insulin resistance early is not academic — it changes management fundamentally.

Fasting insulin — the most direct measure 

Fasting serum insulin is the most direct measure of basal insulin secretion and the test most likely to identify insulin resistance before glucose abnormalities develop. This is critical: glucose dysregulation is a late consequence of insulin resistance. A woman can have severe insulin resistance for years while her fasting glucose remains entirely normal, because the pancreas compensates by producing ever-more insulin.

Interpreting fasting insulin:

• Conventionally "normal" laboratory range: typically <25 µIU/mL
• Functionally optimal for metabolic health: <10 µIU/mL
• Suggestive of insulin resistance: >15–20 µIU/mL
• Clearly elevated: >25 µIU/mL

Many women are told their insulin is "normal" based on lab reference ranges that include the upper end of an insulin-resistant population. A result of 22 µIU/mL may sit within the reference range and still reflect significant insulin resistance. This is why absolute values must be interpreted in context, not simply compared to a laboratory's printed range.

HOMA-IR — calculating insulin resistance from two numbers

The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) uses fasting insulin and fasting glucose together to estimate the degree of insulin resistance at the level of the liver and muscle:

HOMA-IR = (Fasting Insulin [µIU/mL] × Fasting Glucose [mmol/L]) ÷ 22.5

Or, if glucose is in mg/dL: (Fasting Insulin × Fasting Glucose) ÷ 405

HOMA-IR interpretation:

A HOMA-IR ≥2.0 in the clinical PCOS context warrants dietary, lifestyle, and often pharmacological intervention. A score ≥3.5 in a woman with PCOS is associated with a substantially higher risk of metabolic syndrome and future type 2 diabetes [15].

HbA1c — the long-term glucose picture

HbA1c measures average blood glucose over the previous 8–12 weeks by quantifying glycated haemoglobin. It is the standard screening tool for pre-diabetes and diabetes (pre-diabetes: 39–47 mmol/mol or 5.7–6.4%; diabetes: ≥48 mmol/mol or ≥6.5%).

A critical limitation in PCOS: because HbA1c reflects glucose, not insulin, it can remain entirely normal in the presence of substantial insulin resistance. A woman producing three times the normal insulin to maintain normoglycaemia will have a normal HbA1c. This is not reassurance — it is her pancreas working overtime. HbA1c is a useful complement to fasting insulin and HOMA-IR, not a replacement.

The oral glucose tolerance test (OGTT) — the gold standard

The 75g oral glucose tolerance test, in which blood glucose is measured at baseline and then 2 hours after a standard glucose load, is the most sensitive clinical test for identifying impaired glucose tolerance in PCOS. Current guidelines recommend offering a 2-hour OGTT to all women with PCOS, particularly those with obesity, family history of type 2 diabetes, or clinical features of insulin resistance [12].

More informative still is the OGTT with concurrent insulin levels — drawing insulin at 0 and 2 hours alongside glucose. This test identifies the pattern of hyperinsulinaemia in response to a glucose challenge, revealing insulin resistance that is completely invisible on standard glucose or HbA1c testing. A 2-hour insulin above 60–80 µIU/mL is generally considered elevated. This test is not routinely ordered in most clinical settings, which is a significant gap given its diagnostic utility in PCOS.

Fasting lipid panel — the cardiovascular risk piece

The dyslipidaemia pattern in PCOS is characteristic: low HDL cholesterol, elevated triglycerides, and normal or mildly elevated LDL — the same atherogenic lipid profile associated with insulin resistance and metabolic syndrome [16]. This pattern persists even after adjusting for BMI, indicating it is an intrinsic feature of the syndrome rather than simply a consequence of weight.

Key values to assess:

A further note on LDL: standard LDL measurement may underestimate cardiovascular risk in PCOS. Small, dense LDL particles — which are more atherogenic than large LDL — are preferentially elevated in insulin-resistant states. Where cardiovascular risk assessment is a priority, ApoB or LDL particle number adds meaningful precision.

Related Read: Hormonal Health & Metabolism in Women: PCOS, Thyroid, Menopause Help Near You

Thyroid Labs — Ruling Out the Great Mimicker

Thyroid dysfunction is the single most important condition to exclude in any PCOS workup. Both hypothyroidism and hyperthyroidism can produce menstrual irregularity, anovulation, weight changes, and mood disturbance — a symptom overlap extensive enough to cause diagnostic confusion in either direction.

TSH — the screening test

Thyroid-stimulating hormone (TSH) is the appropriate first-line thyroid test and is sufficiently sensitive to detect the majority of clinically significant thyroid dysfunction. However, the conventional "normal" TSH reference range (typically 0.4–4.0 mIU/L) is a subject of ongoing debate. Some endocrinologists and functional medicine practitioners consider a TSH above 2.0–2.5 mIU/L in a symptomatic woman to warrant further investigation, particularly in the context of positive thyroid antibodies [17].

Free T3 and free T4 — when to go further

If TSH is abnormal, or if symptoms strongly suggest thyroid dysfunction despite normal TSH, free T4 (the primary thyroid hormone secreted by the gland) and free T3 (the active, tissue-level form) should be measured. Isolated low free T3 with normal TSH can occur in states of chronic stress, caloric restriction, or inflammation — conditions that are not uncommon in women with PCOS — and can contribute to fatigue and metabolic slowing.

Thyroid antibodies — TPO and TgAb

Anti-thyroid peroxidase antibodies (TPO-Ab) and anti-thyroglobulin antibodies (TgAb) are the markers of Hashimoto's thyroiditis, the autoimmune thyroid disease that eventually leads to hypothyroidism. The clinical relationship between PCOS and Hashimoto's is substantial: multiple studies have found a two to three times higher prevalence of thyroid autoimmunity in women with PCOS compared to age-matched controls [18]. Some researchers have proposed shared immune dysregulation as a common mechanism.

Women with PCOS and positive thyroid antibodies should be monitored for evolving thyroid dysfunction even if TSH is currently normal, as antibody-positive euthyroid status frequently progresses to overt hypothyroidism over time.

Adrenal and Cortisol Labs — Stress, Androgens, and PCOS 

17-hydroxyprogesterone — ruling out congenital adrenal hyperplasia {#17ohp}

Non-classical congenital adrenal hyperplasia (NC-CAH), caused by partial deficiency of the enzyme 21-hydroxylase, is the most common single-gene disorder affecting adrenal steroid synthesis and produces a clinical picture — irregular cycles, elevated androgens, hirsutism — that is indistinguishable from PCOS on clinical examination alone. Prevalence estimates in women presenting with PCOS-like symptoms range from 1–10% depending on ethnic background (it is more prevalent in Ashkenazi Jewish, Hispanic, and Mediterranean populations) [19].

The screening test is 17-hydroxyprogesterone (17-OHP) drawn in the early follicular phase. Values below 2 ng/mL largely exclude NC-CAH. Values above 2 ng/mL, and certainly above 10 ng/mL, warrant an ACTH stimulation test (Synacthen test), in which 17-OHP is measured before and 60 minutes after intravenous ACTH administration. An exaggerated post-stimulation response confirms the diagnosis.

This distinction matters clinically: NC-CAH is treated with low-dose corticosteroids, not the ovarian/insulin-targeted therapies used in PCOS. Misdiagnosis leads to ineffective treatment.

Cortisol and HPA axis dysregulation

The hypothalamic–pituitary–adrenal (HPA) axis is measurably dysregulated in a significant proportion of women with PCOS, contributing to both elevated adrenal androgen production and altered stress responses [20]. Clinically, the most useful cortisol assessments are:

• Morning serum cortisol (8–9am): screens for cortisol excess or insufficiency
• 24-hour urine free cortisol: total cortisol output; elevated in Cushing's syndrome, which must be excluded in women with central adiposity and PCOS-like features
• Late-night salivary cortisol: sensitive measure of cortisol secretion pattern; loss of the normal diurnal decline is a feature of hypercortisolaemia

Overt Cushing's syndrome is rare, but its exclusion is clinically important before attributing hyperandrogenism and insulin resistance purely to PCOS.

Inflammation and Advanced PCOS Biomarkers 

PCOS is increasingly understood as a state of chronic low-grade inflammation — not merely a reproductive or endocrine disorder. This inflammatory component amplifies insulin resistance, drives cardiovascular risk, and may contribute directly to ovarian dysfunction [21]. The following markers extend the standard panel and are particularly valuable for women seeking a more complete metabolic picture.

High-sensitivity CRP (hsCRP)

High-sensitivity C-reactive protein is the most widely available marker of systemic inflammation. In PCOS, hsCRP levels are consistently elevated compared to controls, independent of BMI, suggesting that inflammation is intrinsic to the syndrome rather than solely a product of obesity-associated adipose tissue inflammation [22]. A hsCRP above 3 mg/L places a woman in the higher cardiovascular risk category according to American Heart Association guidelines — a threshold that a significant proportion of women with PCOS meet.

Homocysteine

Elevated homocysteine — an amino acid produced during methionine metabolism — is an independent cardiovascular risk factor and is associated with increased risk of miscarriage and impaired implantation, making it particularly relevant in women with PCOS pursuing pregnancy. Elevated homocysteine in PCOS may reflect impaired folate and B12 metabolism, sometimes exacerbated by metformin therapy, which reduces B12 absorption over time.

Vitamin D

Vitamin D deficiency is extraordinarily prevalent in women with PCOS — estimated at 67–85% depending on the population studied [24]. Vitamin D receptors are expressed on ovarian granulosa cells, and deficiency has been linked to impaired folliculogenesis, worsened insulin resistance, and higher androgen levels. Serum 25-hydroxyvitamin D (25-OH-D) below 50 nmol/L (20 ng/mL) constitutes deficiency; optimal levels for metabolic function are generally considered to be above 75–100 nmol/L (30–40 ng/mL).

Ferritin and iron studies

Iron status assessment in PCOS is nuanced. Heavy menstrual bleeding — which affects some women with PCOS despite infrequent periods, particularly when breakthrough bleeding occurs — can produce iron deficiency anaemia. However, ferritin, as an acute-phase reactant, is also elevated in inflammatory states and cannot always be used as a straightforward marker of iron stores in PCOS. A full iron panel (serum iron, ferritin, transferrin saturation, TIBC) provides more interpretable data than ferritin alone.

Liver function tests (LFTs)

Non-alcoholic fatty liver disease (NAFLD) affects up to 30–55% of women with PCOS, driven by insulin resistance and dyslipidaemia [25]. Elevated ALT and AST in the context of PCOS warrant further investigation, including liver ultrasound. Routine LFTs are a low-cost, high-yield screen in this population and should not be omitted.

Complete blood count (CBC)

A full blood count is a basic but essential component of the workup — identifying anaemia (relevant in heavy bleeders), elevated WBC suggesting chronic infection or inflammation, and haematocrit changes. Its value is supportive rather than diagnostic for PCOS specifically.

When to Get Tested — Timing, Cycle Day, and Fasting Requirements

Timing matters enormously for hormonal labs, and obtaining blood at the wrong time of cycle or day can produce misleading results — both false reassurance and spurious abnormalities.

Cycle day timing for hormonal labs

For women with highly irregular cycles or amenorrhoea, a random draw is preferable to waiting indefinitely for day 2–5. In this context, noting the day of draw on the lab request allows the interpreting clinician to contextualise results appropriately.

Fasting requirements

Water is always permitted during a fast. Vigorous exercise in the 24 hours before draws can artefactually alter several values (testosterone, cortisol, prolactin, glucose) and should be minimised before testing.

Testing on hormonal contraception

Oral contraceptive pills, hormonal IUDs, and implants directly suppress the hypothalamic–pituitary–ovarian axis and will profoundly alter hormonal lab values. Specifically:

• Combined OCP suppresses LH, FSH, and androgens, and substantially raises SHBG — making free testosterone and FAI uninterpretable
• Progestogen-only methods are more variable in their suppression
• Testosterone, AMH, and androgens are all affected by OCP use

For diagnostic purposes, hormone testing is ideally conducted after a minimum 3-month washout from combined oral contraceptive pills. Where this is not clinically possible, metabolic labs (insulin, glucose, HOMA-IR, lipids) remain fully interpretable on contraception and should proceed without delay.

How to Read Your PCOS Lab Results 

One of the most common frustrations women with PCOS experience is being told their results are "normal" and sent home — when, in fact, their results are borderline, poorly timed, or interpreted against a reference range that was never designed with PCOS in mind.

Why "within normal range" is not the same as optimal

Laboratory reference ranges are typically constructed from the central 95th percentile of a large population sample. That population is not selected for metabolic health. The implication: the upper end of "normal" fasting insulin, for example, includes insulin-resistant individuals. A result of 22 µIU/mL is technically within the reference range of most laboratories, yet it reflects the same degree of insulin resistance that drives progressive metabolic disease.

The distinction between population reference ranges and functional optimal ranges is essential for interpreting PCOS labs. The former tells you where you sit relative to the population; the latter tells you where you need to be for optimal metabolic and reproductive health.

Red flag patterns on PCOS labs

How labs shift with treatment

Understanding the expected trajectory of lab values during treatment is clinically important for monitoring response. General patterns:

After starting metformin: Fasting insulin and HOMA-IR typically improve within 3–6 months. Testosterone and androgen markers may improve modestly. LH:FSH ratio may normalise. AMH is not reliably affected by metformin.

After inositol supplementation (myo-inositol ± D-chiro-inositol): Fasting insulin, HOMA-IR, and testosterone can improve within 3–6 months, particularly in lean or insulin-resistant phenotypes. AMH has been reported to decrease with inositol supplementation in some studies.

During weight loss (5–10% body weight): SHBG rises (reducing free androgen activity), testosterone may fall into normal range, HOMA-IR improves substantially, AMH may decrease toward normal range, menstrual cycle regularity often improves.

Repeat labs should be scheduled at 3–6-month intervals when initiating or changing management, and at minimum annually once stable.

Complete PCOS Lab Panels by Scenario 

The following scenario-based panels are clinical recommendations, not replacements for individualised clinical assessment. They are designed to help women advocate for appropriate testing with their healthcare provider.

Essential starter panel — first-time PCOS workup

For a woman presenting with suspected PCOS and no prior investigation:

Comprehensive PCOS metabolic panel

For women with known or suspected insulin resistance, metabolic syndrome, or weight concerns:

Includes all of the above, plus: androstenedione, 25-OH vitamin D, hsCRP, homocysteine, ApoB (if cardiovascular risk is a concern), 2-hour OGTT with insulin levels, ferritin with iron studies

Panel for PCOS and fertility / trying to conceive

All starter panel tests, plus: Day-21 progesterone (to confirm ovulation), thyroid antibodies (TPO and TgAb), homocysteine, folate, B12, vitamin D, mid-cycle LH (for ovulation tracking context), fasting insulin (insulin resistance impairs implantation)

Panel for PCOS and hair loss (androgenic alopecia)

All starter panel tests, with specific attention to: free testosterone, FAI, androstenedione, SHBG, ferritin (low ferritin independently causes hair loss), thyroid panel including T3, DHEA-S, and 17-OHP (to exclude NC-CAH)

Annual monitoring labs — once diagnosed

TSH, fasting glucose, fasting insulin, HOMA-IR, HbA1c, full lipid panel, LFTs, vitamin D, total and free testosterone. Adding hsCRP annually provides a useful cardiovascular risk trend.

How to ask your doctor for the right tests

Many women encounter resistance when requesting a comprehensive panel. Practical framing:

"I'm here because I have symptoms consistent with PCOS — irregular cycles, signs of androgen excess, and fatigue. I'd like to investigate this comprehensively. Can we include fasting insulin and HOMA-IR alongside the standard hormone panel? I'm particularly concerned about insulin resistance as a driver."

If a clinician declines to order fasting insulin specifically, a reasonable alternative is to request an HbA1c and 2-hour OGTT. If full investigation is not available through your GP or gynaecologist, a referral to an endocrinologist is appropriate — and direct-to-consumer laboratory services offer many of these tests independently in most countries.

Healthcare Navigation and Getting the Right Tests Ordered 

Why PCOS is persistently under-diagnosed

The diagnostic delay in PCOS — averaging 2 years from first presentation to diagnosis, and often considerably longer — is not a mystery. It reflects the intersection of several systemic problems: the absence of a single diagnostic test, symptom normalisation by clinicians ("irregular periods are common"), inadequate awareness of PCOS in non-reproductive presentations (metabolic PCOS in a lean woman, for example), and the Rotterdam Criteria's inherent breadth, which creates interpretive latitude that is sometimes exercised in the wrong direction.

Understanding this context helps women advocate effectively. A diagnosis of PCOS is not self-evident from labs alone — but arriving at a consultation with detailed symptom history, menstrual records, and knowledge of what labs are indicated is a meaningful clinical contribution.

What to do if your doctor declines to test

If you are unable to access the full panel through your primary care provider:

• Request a specialist referral — an endocrinologist or reproductive endocrinologist (if fertility is a concern) is best placed to conduct a comprehensive evaluation
• Direct-to-consumer (DTC) lab testing is available in most countries and provides access to most PCOS markers including fasting insulin, androgens, AMH, and thyroid panels, without a physician's order
• Telehealth platforms with PCOS-specialist clinicians can typically order a comprehensive panel and interpret results in context

What type of doctor to see

A common clinical frustration is that OB-GYNs frequently focus on reproductive features (cycles, fertility) while metabolic workup is deprioritised, while GPs may focus on a limited hormonal screen without the full metabolic panel. An endocrinologist offers the most complete evaluation.

Meto's Take: A Specialist-Designed PCOS Panel 

At Meto, we encounter the clinical gap around PCOS testing regularly. The standard tests ordered in most settings — a testosterone, an FSH, and a TSH — are a starting point, not a workup. They will identify a minority of PCOS cases and characterise almost none of them sufficiently to guide management.

The question we ask is: what does a woman with PCOS actually need to know about her biology in order to make informed decisions — about her diet, her lifestyle, her medication options, and her fertility planning? The answer requires considerably more than a basic hormone screen.

Our PCOS-specific panel was designed by specialists in metabolic medicine and reproductive endocrinology. It goes where most standard panels do not: into the granular detail of androgen fractionation, insulin physiology, thyroid autoimmunity, and inflammatory burden. It is structured not merely to confirm a diagnosis, but to characterise the metabolic phenotype — because two women can both meet the Rotterdam Criteria and have fundamentally different underlying drivers that demand different interventions.

Specifically, Meto's PCOS panel includes:

• Full androgen profile: Total testosterone, free testosterone, SHBG, FAI, DHEA-S, androstenedione
• Reproductive hormone panel: LH, FSH, oestradiol, progesterone, prolactin, AMH
• Complete metabolic assessment: Fasting insulin, fasting glucose, HOMA-IR, HbA1c, full lipid panel, LFTs
• Thyroid panel: TSH, free T3, free T4, TPO antibodies
• Exclusion markers: 17-OHP (to exclude NC-CAH)
• Advanced metabolic markers: hsCRP, vitamin D, homocysteine

Every result is accompanied by a clinician-written interpretation — not a lab report with reference ranges, but a contextualised explanation of what the pattern means for you specifically, and what next steps are warranted. We believe that getting tested is only half the work; understanding what the results mean is where outcomes are changed.

Order your PCOS panel →

Frequently Asked Questions

What is the best blood test for PCOS?

There is no single best test, because PCOS is a syndrome — a collection of features rather than one pathology. The most clinically informative tests are free testosterone (or FAI via SHBG), AMH, and fasting insulin — because these three together capture androgen excess, ovarian morphology, and metabolic status, the three pillars of PCOS characterisation. If you could only order three tests, these would be the most useful.

Can you have normal labs and still have PCOS?

Yes. This is one of the most important things to understand about PCOS testing. Approximately 20–40% of women with PCOS have total testosterone within normal limits; a significant proportion have normal LH:FSH ratios; and those on hormonal contraception will have suppressed androgens regardless of their underlying physiology. PCOS is a clinical diagnosis supported by labs, not determined by them. "Normal" labs in the context of a classic symptom picture should prompt more careful fractionation of androgens, AMH measurement, and review of test timing.

Does hormonal birth control affect PCOS lab results?

Significantly. Combined oral contraceptive pills suppress LH, FSH, testosterone, and AMH while dramatically raising SHBG — making the hormonal picture uninterpretable for diagnostic purposes. Metabolic labs (insulin, glucose, lipids) remain valid on contraception and can still be used to assess metabolic status. For a complete hormonal workup, a 3-month washout period from combined OCP is the standard recommendation.

What labs show insulin resistance in PCOS?

Fasting insulin and HOMA-IR are the primary tools. A fasting insulin above 15–20 µIU/mL or a HOMA-IR above 2.0 in a woman with PCOS is clinically significant, even within laboratory "normal" ranges. The 2-hour OGTT with concurrent insulin levels is the most sensitive test and will identify insulin resistance in women whose fasting values are borderline.

Is AMH a reliable test for PCOS?

AMH is the most consistently elevated lab marker across all PCOS phenotypes and correlates well with antral follicle count on ultrasound. It is not yet part of the diagnostic criteria because of inter-assay variability, but it is a reliable supporting marker, particularly when ultrasound is unavailable or of poor quality. A very high AMH (>35–40 pmol/L in reproductive-age women) in the context of other features is clinically meaningful.

What is the most important lab marker for PCOS?

For reproductive diagnosis: free testosterone or FAI. For metabolic characterisation: fasting insulin or HOMA-IR. For overall PCOS morphology assessment: AMH.

There is no single most important marker — the panel's value lies in the combination.

Can PCOS be diagnosed without a blood test?

Technically, yes — two of the three Rotterdam Criteria (clinical hyperandrogenism and polycystic ovarian morphology on ultrasound) can be established without blood tests. In practice, biochemical androgen measurement is strongly recommended in all cases to characterise severity, guide treatment, and exclude conditions that mimic PCOS. A diagnosis made without labs is incomplete.

How often should PCOS labs be repeated?

Once diagnosed and stable, annual metabolic monitoring (insulin, glucose, HbA1c, lipids) is a minimum standard. Hormonal labs can be reviewed at the same frequency or more often if treatment has been initiated or changed. AMH is typically repeated no more than annually, as it changes slowly.

This article is written for educational purposes and does not constitute personalised medical advice. Always consult a qualified healthcare provider for diagnosis and treatment. For specialist-designed PCOS testing, visit meto.co.